ONTOLOGY REPORT - ANNOTATIONS
| Term: | 3-oxo steroid |
|
| Accession: | CHEBI:47788
|
browse the term
|
| Definition: | Any oxo steroid where an oxo substituent is located at position 3. |
| Synonyms: | related_synonym: | 3-Oxosteroid; 3-oxo steroids; 3-oxosteroid; 3-oxosteroids; a 3-oxosteroid |
| | alt_id: | CHEBI:13607; CHEBI:1653; CHEBI:20182; CHEBI:71186 |
| | xref: | KEGG COMPOUND:C01876 "KEGG COMPOUND"; SUBMITTER:9811880 "PubMed citation" |
|
|
17beta-hydroxy-5alpha-androstan-3-one
|
| G |
Acaca |
acetyl-CoA carboxylase alpha |
|
decreases phosphorylation |
ISO |
10 |
72,483,772 |
72,677,134 |
RGD:6480464 |
CTD |
| G |
Acaca |
acetyl-CoA carboxylase alpha |
|
decreases expression |
ISO |
10 |
72,483,772 |
72,677,134 |
RGD:6480464 |
CTD |
| G |
Acacb |
acetyl-CoA carboxylase beta |
|
decreases phosphorylation |
ISO |
12 |
43,388,679 |
43,492,993 |
RGD:6480464 |
CTD |
| G |
Acpp |
acid phosphatase, prostate |
|
decreases expression |
ISO |
8 |
109,354,381 |
109,400,296 |
RGD:6480464 |
CTD |
| G |
Acyp2 |
acylphosphatase 2, muscle type |
|
increases expression |
ISO |
14 |
111,507,725 |
111,512,680 |
RGD:6480464 |
CTD |
| G |
Acyp2-ps1 |
acylphosphatase 2, muscle type, pseudogene 1 |
|
increases expression |
ISO |
14 |
111,836,252 |
111,836,724 |
RGD:6480464 |
CTD |
| G |
Adam9 |
ADAM metallopeptidase domain 9 |
|
multiple interactions |
ISO |
16 |
71,446,498 |
71,526,108 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
increases expression |
ISO |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
multiple interactions |
ISO |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Adcyap1r1 |
adenylate cyclase activating polypeptide 1 receptor 1 |
|
increases expression |
ISO |
4 |
84,209,729 |
84,254,982 |
RGD:6480464 |
CTD |
| G |
Adm |
adrenomedullin |
|
multiple interactions |
EXP |
1 |
168,380,255 |
168,382,426 |
RGD:6480464 |
CTD |
| G |
Adm |
adrenomedullin |
|
increases expression |
EXP |
1 |
168,380,255 |
168,382,426 |
RGD:6480464 |
CTD |
| G |
Aes |
amino-terminal enhancer of split |
|
increases expression |
ISO |
7 |
9,616,545 |
9,621,697 |
RGD:6480464 |
CTD |
| G |
Agps |
alkylglycerone phosphate synthase |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Agr2 |
anterior gradient 2 homolog (Xenopus laevis) |
|
affects expression |
ISO |
6 |
54,695,633 |
54,716,858 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
affects binding |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
|
multiple interactions |
ISO |
17 |
77,084,306 |
77,112,994 |
RGD:6480464 |
CTD |
| G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
|
increases metabolic processing |
ISO |
17 |
77,084,306 |
77,112,994 |
RGD:6480464 |
CTD |
| G |
Akr1c14 |
aldo-keto reductase family 1, member C14 |
|
increases metabolic processing |
EXP |
17 |
77,316,456 |
77,332,903 |
RGD:6480464 |
CTD |
| G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
multiple interactions |
ISO |
17 |
77,034,737 |
77,081,406 |
RGD:6480464 |
CTD |
| G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
increases reduction |
ISO |
17 |
77,034,737 |
77,081,406 |
RGD:6480464 |
CTD |
| G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
increases metabolic processing |
ISO |
17 |
77,034,737 |
77,081,406 |
RGD:6480464 |
CTD |
| G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
multiple interactions |
ISO |
17 |
77,034,737 |
77,081,406 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
increases metabolic processing |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases activity |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
|
multiple interactions |
ISO |
1 |
120,847,746 |
120,881,883 |
RGD:6480464 |
CTD |
| G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
|
increases expression |
ISO |
1 |
120,847,746 |
120,881,883 |
RGD:6480464 |
CTD |
| G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
|
increases activity |
ISO |
1 |
120,847,746 |
120,881,883 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
increases expression |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Apoe |
apolipoprotein E |
|
multiple interactions |
ISO |
1 |
79,003,634 |
79,006,387 |
RGD:6480464 |
CTD |
| G |
Apoe |
apolipoprotein E |
|
affects response to substance |
ISO |
1 |
79,003,634 |
79,006,387 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
decreases expression |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Aqp9 |
aquaporin 9 |
|
increases expression |
EXP |
8 |
75,611,485 |
75,651,646 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects response to substance |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases localization |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects localization |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases localization |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Atf3 |
activating transcription factor 3 |
|
increases expression |
ISO |
13 |
107,191,622 |
107,223,850 |
RGD:6480464 |
CTD |
| G |
Atf4 |
activating transcription factor 4 |
|
increases expression |
ISO |
7 |
118,537,718 |
118,538,994 |
RGD:6480464 |
CTD |
| G |
Atp1b3 |
ATPase, Na+/K+ transporting, beta 3 polypeptide |
|
decreases expression |
ISO |
8 |
101,405,877 |
101,437,757 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcar1 |
breast cancer anti-estrogen resistance 1 |
|
increases expression |
ISO |
19 |
41,646,190 |
41,669,234 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bglap |
bone gamma-carboxyglutamate (gla) protein |
|
increases expression |
ISO |
2 |
180,482,313 |
180,483,290 |
RGD:6480464 |
CTD |
| G |
Bglap |
bone gamma-carboxyglutamate (gla) protein |
|
increases expression |
ISO |
2 |
180,482,313 |
180,483,290 |
RGD:6480464 |
CTD |
| G |
Bglap |
bone gamma-carboxyglutamate (gla) protein |
|
increases expression |
ISO |
2 |
180,482,313 |
180,483,290 |
RGD:6480464 |
CTD |
| G |
Bmpr1b |
bone morphogenetic protein receptor, type IB |
|
increases expression |
ISO |
2 |
239,727,569 |
239,767,802 |
RGD:6480464 |
CTD |
| G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
|
increases expression |
ISO |
3 |
105,063,018 |
105,116,145 |
RGD:6480464 |
CTD |
| G |
Cacybp |
calcyclin binding protein |
|
increases expression |
ISO |
13 |
75,623,161 |
75,633,644 |
RGD:6480464 |
CTD |
| G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2, beta |
|
multiple interactions |
ISO |
12 |
34,907,317 |
34,938,479 |
RGD:6480464 |
CTD |
| G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2, beta |
|
increases expression |
ISO |
12 |
34,907,317 |
34,938,479 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cbs |
cystathionine beta synthase |
|
decreases expression |
ISO |
20 |
10,047,478 |
10,075,520 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
increases expression |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
increases expression |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
increases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnb2 |
cyclin B2 |
|
increases expression |
ISO |
8 |
74,892,108 |
74,906,181 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
increases expression |
ISO |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Cd40 |
CD40 molecule, TNF receptor superfamily member 5 |
|
multiple interactions |
ISO |
3 |
156,092,602 |
156,107,427 |
RGD:6480464 |
CTD |
| G |
Cd83 |
CD83 molecule |
|
increases expression |
ISO |
17 |
26,705,646 |
26,725,470 |
RGD:6480464 |
CTD |
| G |
Cdc20 |
cell division cycle 20 |
|
increases expression |
ISO |
5 |
138,913,180 |
138,916,744 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
increases expression |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk5rap2 |
CDK5 regulatory subunit associated protein 2 |
|
decreases expression |
ISO |
5 |
87,564,010 |
87,738,257 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
decreases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
decreases expression |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
decreases expression |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Chek2 |
checkpoint kinase 2 |
|
multiple interactions |
ISO |
12 |
45,933,900 |
45,965,427 |
RGD:6480464 |
CTD |
| G |
Chpf |
chondroitin polymerizing factor |
|
increases expression |
ISO |
9 |
74,749,945 |
74,754,639 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
multiple interactions |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
decreases expression |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
increases activity |
ISO |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
increases activity |
EXP |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
multiple interactions |
ISO |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
multiple interactions |
ISO |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
decreases expression |
ISO |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
increases expression |
ISO |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Col6a1 |
collagen, type VI, alpha 1 |
|
decreases expression |
ISO |
20 |
12,320,102 |
12,338,500 |
RGD:6480464 |
CTD |
| G |
Coro1b |
coronin, actin-binding protein, 1B |
|
decreases expression |
EXP |
1 |
206,733,360 |
206,738,018 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Crebbp |
CREB binding protein |
|
multiple interactions |
ISO |
10 |
11,598,680 |
11,724,122 |
RGD:6480464 |
CTD |
| G |
Csf1 |
colony stimulating factor 1 (macrophage) |
|
decreases expression |
ISO |
2 |
203,292,765 |
203,307,968 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csnk2a1 |
casein kinase 2, alpha 1 polypeptide |
|
decreases expression |
ISO |
3 |
142,564,754 |
142,609,311 |
RGD:6480464 |
CTD |
| G |
Cst8 |
cystatin 8 (cystatin-related epididymal specific) |
|
decreases expression |
ISO |
3 |
137,557,637 |
137,564,274 |
RGD:6480464 |
CTD |
| G |
Cst8 |
cystatin 8 (cystatin-related epididymal specific) |
|
increases expression |
ISO |
3 |
137,557,637 |
137,564,274 |
RGD:6480464 |
CTD |
| G |
Ctcf |
CCCTC-binding factor (zinc finger protein) |
|
decreases expression |
ISO |
19 |
35,461,942 |
35,514,934 |
RGD:6480464 |
CTD |
| G |
Ctnna1 |
catenin (cadherin-associated protein), alpha 1, 102kDa |
|
decreases expression |
ISO |
18 |
27,629,915 |
27,769,360 |
RGD:6480464 |
CTD |
| G |
Ctsl1 |
cathepsin L1 |
|
decreases expression |
ISO |
17 |
6,288,013 |
6,294,174 |
RGD:6480464 |
CTD |
| G |
Cux2 |
cut-like homeobox 2 |
|
decreases expression |
ISO |
12 |
35,850,093 |
35,910,414 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl12 |
chemokine (C-X-C motif) ligand 12 |
|
decreases expression |
ISO |
4 |
153,503,576 |
153,516,423 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
3 |
161,542,131 |
161,553,801 |
RGD:6480464 |
CTD |
| G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
3 |
161,542,131 |
161,553,801 |
RGD:6480464 |
CTD |
| G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
241,945,472 |
241,949,220 |
RGD:6480464 |
CTD |
| G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
2 |
103,102,679 |
103,271,273 |
RGD:6480464 |
CTD |
| G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
|
decreases expression |
ISO |
2 |
103,102,679 |
103,271,273 |
RGD:6480464 |
CTD |
| G |
Dbi |
diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
|
decreases expression |
ISO |
1 |
156,447,588 |
156,478,740 |
RGD:6480464 |
CTD |
| G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
|
increases expression |
ISO |
11 |
84,922,649 |
84,927,694 |
RGD:6480464 |
CTD |
| G |
Dhcr24 |
24-dehydrocholesterol reductase |
|
affects expression |
ISO |
5 |
127,637,438 |
127,662,621 |
RGD:6480464 |
CTD |
| G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
|
increases expression |
ISO |
1 |
234,392,743 |
234,396,426 |
RGD:6480464 |
CTD |
| G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
|
multiple interactions |
ISO |
1 |
234,392,743 |
234,396,426 |
RGD:6480464 |
CTD |
| G |
Dynll1 |
dynein light chain LC8-type 1 |
|
increases expression |
ISO |
12 |
42,580,542 |
42,582,915 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
increases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
increases expression |
ISO |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Eif2a |
eukaryotic translation initiation factor 2A |
|
multiple interactions |
ISO |
2 |
147,870,265 |
147,903,411 |
RGD:6480464 |
CTD |
| G |
Eif2a |
eukaryotic translation initiation factor 2A |
|
increases phosphorylation |
ISO |
2 |
147,870,265 |
147,903,411 |
RGD:6480464 |
CTD |
| G |
Emp2 |
epithelial membrane protein 2 |
|
increases expression |
ISO |
10 |
5,311,157 |
5,348,038 |
RGD:6480464 |
CTD |
| G |
Enc1 |
ectodermal-neural cortex 1 |
|
decreases expression |
ISO |
2 |
27,720,805 |
27,733,168 |
RGD:6480464 |
CTD |
| G |
Ep300 |
E1A binding protein p300 |
|
multiple interactions |
ISO |
7 |
119,938,507 |
120,008,886 |
RGD:6480464 |
CTD |
| G |
Ep300 |
E1A binding protein p300 |
|
multiple interactions |
ISO |
7 |
119,938,507 |
120,008,886 |
RGD:6480464 |
CTD |
| G |
Ep300 |
E1A binding protein p300 |
|
multiple interactions |
ISO |
7 |
119,938,507 |
120,008,886 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases activity |
EXP |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects response to substance |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
decreases expression |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases activity |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases localization |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Etl4 |
enhancer trap locus 4 |
|
multiple interactions |
ISO |
17 |
94,757,415 |
94,770,668 |
RGD:6480464 |
CTD |
| G |
Etl4 |
enhancer trap locus 4 |
|
decreases expression |
ISO |
17 |
94,757,415 |
94,770,668 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
decreases expression |
ISO |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
decreases expression |
ISO |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fam193a |
family with sequence similarity 193, member A |
|
increases expression |
ISO |
14 |
81,898,783 |
81,981,572 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fbxl16 |
F-box and leucine-rich repeat protein 16 |
|
decreases expression |
ISO |
10 |
15,082,199 |
15,085,374 |
RGD:6480464 |
CTD |
| G |
Fbxo28 |
F-box protein 28 |
|
decreases expression |
ISO |
13 |
98,317,300 |
98,342,771 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
increases expression |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
decreases expression |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fhl2 |
four and a half LIM domains 2 |
|
multiple interactions |
ISO |
9 |
42,319,997 |
42,349,055 |
RGD:6480464 |
CTD |
| G |
Figf |
c-fos induced growth factor |
|
increases expression |
ISO |
X |
50,830,612 |
50,864,445 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
increases expression |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Folh1 |
folate hydrolase 1 |
|
increases expression |
ISO |
1 |
142,936,379 |
143,010,358 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosl1 |
fos-like antigen 1 |
|
increases expression |
ISO |
1 |
208,090,612 |
208,099,118 |
RGD:6480464 |
CTD |
| G |
Foxa1 |
forkhead box A1 |
|
multiple interactions |
ISO |
6 |
77,976,384 |
78,009,176 |
RGD:6480464 |
CTD |
| G |
Foxa2 |
forkhead box A2 |
|
multiple interactions |
ISO |
3 |
136,739,009 |
136,743,204 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
multiple interactions |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
increases expression |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
multiple interactions |
EXP |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fst |
follistatin |
|
decreases expression |
ISO |
2 |
46,542,246 |
46,550,678 |
RGD:6480464 |
CTD |
| G |
Fzd6 |
frizzled family receptor 6 |
|
decreases expression |
ISO |
7 |
74,562,307 |
74,594,014 |
RGD:6480464 |
CTD |
| G |
Gad2 |
glutamate decarboxylase 2 |
|
decreases expression |
EXP |
17 |
96,259,430 |
96,321,857 |
RGD:6480464 |
CTD |
| G |
Gas6 |
growth arrest specific 6 |
|
multiple interactions |
ISO |
16 |
80,900,159 |
80,930,929 |
RGD:6480464 |
CTD |
| G |
Gas6 |
growth arrest specific 6 |
|
increases expression |
ISO |
16 |
80,900,159 |
80,930,929 |
RGD:6480464 |
CTD |
| G |
Gata2 |
GATA binding protein 2 |
|
multiple interactions |
ISO |
4 |
122,279,753 |
122,288,528 |
RGD:6480464 |
CTD |
| G |
Gdf15 |
growth differentiation factor 15 |
|
increases expression |
ISO |
16 |
19,310,882 |
19,313,465 |
RGD:6480464 |
CTD |
| G |
Gjb3 |
gap junction protein, beta 3 |
|
decreases expression |
ISO |
5 |
146,771,804 |
146,772,616 |
RGD:6480464 |
CTD |
| G |
Gpi |
glucose-6-phosphate isomerase |
|
increases expression |
ISO |
1 |
86,658,836 |
86,686,712 |
RGD:6480464 |
CTD |
| G |
Gpx5 |
glutathione peroxidase 5 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Gtf2i |
general transcription factor II I |
|
increases expression |
ISO |
12 |
23,470,042 |
23,545,621 |
RGD:6480464 |
CTD |
| G |
Hmgn1 |
high mobility group nucleosome binding domain 1 |
|
increases expression |
ISO |
11 |
36,429,800 |
36,435,719 |
RGD:6480464 |
CTD |
| G |
Hoxb2 |
homeobox B2 |
|
increases expression |
EXP |
10 |
85,085,425 |
85,087,617 |
RGD:6480464 |
CTD |
| G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
|
increases expression |
ISO |
9 |
11,033,496 |
11,038,868 |
RGD:6480464 |
CTD |
| G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
|
decreases expression |
ISO |
9 |
11,033,496 |
11,038,868 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Id1 |
inhibitor of DNA binding 1 |
|
increases expression |
ISO |
3 |
143,086,162 |
143,087,289 |
RGD:6480464 |
CTD |
| G |
Id2 |
inhibitor of DNA binding 2 |
|
increases expression |
ISO |
6 |
42,781,476 |
42,783,307 |
RGD:6480464 |
CTD |
| G |
Id3 |
inhibitor of DNA binding 3 |
|
increases expression |
ISO |
5 |
154,934,138 |
154,935,707 |
RGD:6480464 |
CTD |
| G |
Id4 |
inhibitor of DNA binding 4 |
|
increases expression |
ISO |
17 |
22,525,292 |
22,527,861 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
multiple interactions |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases expression |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases secretion |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
decreases expression |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
multiple interactions |
ISO |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
increases expression |
ISO |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
|
multiple interactions |
ISO |
9 |
71,966,877 |
71,994,211 |
RGD:6480464 |
CTD |
| G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
|
increases expression |
ISO |
9 |
71,966,877 |
71,994,211 |
RGD:6480464 |
CTD |
| G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
|
decreases expression |
ISO |
14 |
87,959,153 |
87,967,085 |
RGD:6480464 |
CTD |
| G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
|
decreases secretion |
ISO |
14 |
87,959,153 |
87,967,085 |
RGD:6480464 |
CTD |
| G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
|
increases expression |
ISO |
14 |
87,959,153 |
87,967,085 |
RGD:6480464 |
CTD |
| G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
|
decreases expression |
ISO |
7 |
140,885,388 |
140,890,028 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il7 |
interleukin 7 |
|
increases expression |
ISO |
2 |
96,356,083 |
96,399,796 |
RGD:6480464 |
CTD |
| G |
Ints4 |
integrator complex subunit 4 |
|
increases expression |
ISO |
1 |
154,714,605 |
154,778,362 |
RGD:6480464 |
CTD |
| G |
Itgb1 |
integrin, beta 1 |
|
decreases expression |
ISO |
19 |
58,600,095 |
58,647,531 |
RGD:6480464 |
CTD |
| G |
Kitlg |
KIT ligand |
|
increases expression |
ISO |
7 |
37,714,157 |
37,795,722 |
RGD:6480464 |
CTD |
| G |
Klf3 |
Kruppel-like factor 3 (basic) |
|
increases expression |
ISO |
14 |
46,203,638 |
46,226,077 |
RGD:6480464 |
CTD |
| G |
Klk7 |
kallikrein-related peptidase 7 |
|
increases expression |
ISO |
1 |
94,243,421 |
94,246,711 |
RGD:6480464 |
CTD |
| G |
Krt19 |
keratin 19 |
|
increases expression |
ISO |
10 |
89,080,953 |
89,085,670 |
RGD:6480464 |
CTD |
| G |
Lama5 |
laminin, alpha 5 |
|
increases expression |
ISO |
3 |
169,233,897 |
169,282,410 |
RGD:6480464 |
CTD |
| G |
Lamc1 |
laminin, gamma 1 |
|
increases expression |
ISO |
13 |
68,241,453 |
68,369,419 |
RGD:6480464 |
CTD |
| G |
Lcn5 |
lipocalin 5 |
|
increases expression |
ISO |
3 |
3,825,478 |
3,829,490 |
RGD:6480464 |
CTD |
| G |
Lcn5 |
lipocalin 5 |
|
multiple interactions |
ISO |
3 |
3,825,478 |
3,829,490 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
decreases expression |
ISO |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Lhb |
luteinizing hormone beta |
|
multiple interactions |
ISO |
1 |
95,892,999 |
95,893,988 |
RGD:6480464 |
CTD |
| G |
Lpl |
lipoprotein lipase |
|
increases expression |
ISO |
16 |
22,533,105 |
22,556,905 |
RGD:6480464 |
CTD |
| G |
Lrrc28 |
leucine rich repeat containing 28 |
|
increases expression |
ISO |
1 |
122,267,092 |
122,385,096 |
RGD:6480464 |
CTD |
| G |
Mak |
male germ cell-associated kinase |
|
multiple interactions |
ISO |
17 |
29,644,795 |
29,698,155 |
RGD:6480464 |
CTD |
| G |
Mak |
male germ cell-associated kinase |
|
increases expression |
ISO |
17 |
29,644,795 |
29,698,155 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
multiple interactions |
ISO |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
|
multiple interactions |
ISO |
7 |
10,074,654 |
10,094,003 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk10 |
mitogen activated protein kinase 10 |
|
multiple interactions |
ISO |
14 |
7,719,595 |
8,010,694 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
increases expression |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk6 |
mitogen-activated protein kinase 6 |
|
increases expression |
ISO |
8 |
80,212,726 |
80,236,362 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mcm5 |
minichromosome maintenance complex component 5 |
|
increases expression |
ISO |
19 |
13,978,940 |
14,000,641 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
increases expression |
ISO |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Mef2a |
myocyte enhancer factor 2a |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mef2c |
myocyte enhancer factor 2C |
|
increases expression |
ISO |
2 |
12,331,078 |
12,346,520 |
RGD:6480464 |
CTD |
| G |
Mif |
macrophage migration inhibitory factor (glycosylation-inhibiting factor) |
|
increases expression |
ISO |
20 |
13,191,986 |
13,192,851 |
RGD:6480464 |
CTD |
| G |
Mt2A |
metallothionein 2A |
|
decreases expression |
ISO |
19 |
11,267,811 |
11,268,585 |
RGD:6480464 |
CTD |
| G |
Mybl2 |
myeloblastosis oncogene-like 2 |
|
increases expression |
ISO |
3 |
153,925,908 |
153,954,323 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myh2 |
myosin, heavy chain 2, skeletal muscle, adult |
|
increases expression |
ISO |
10 |
53,864,777 |
53,891,711 |
RGD:6480464 |
CTD |
| G |
Myod1 |
myogenic differentiation 1 |
|
increases expression |
ISO |
1 |
96,910,190 |
96,912,900 |
RGD:6480464 |
CTD |
| G |
Myod1 |
myogenic differentiation 1 |
|
increases expression |
ISO |
1 |
96,910,190 |
96,912,900 |
RGD:6480464 |
CTD |
| G |
Myog |
myogenin |
|
increases expression |
ISO |
13 |
47,243,712 |
47,246,301 |
RGD:6480464 |
CTD |
| G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
multiple interactions |
ISO |
6 |
27,224,396 |
27,473,926 |
RGD:6480464 |
CTD |
| G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
multiple interactions |
ISO |
6 |
27,224,396 |
27,473,926 |
RGD:6480464 |
CTD |
| G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
multiple interactions |
ISO |
6 |
27,224,396 |
27,473,926 |
RGD:6480464 |
CTD |
| G |
Ncoa2 |
nuclear receptor coactivator 2 |
|
multiple interactions |
ISO |
5 |
5,197,891 |
5,275,776 |
RGD:6480464 |
CTD |
| G |
Ncoa2 |
nuclear receptor coactivator 2 |
|
multiple interactions |
ISO |
5 |
5,197,891 |
5,275,776 |
RGD:6480464 |
CTD |
| G |
Ncoa2 |
nuclear receptor coactivator 2 |
|
multiple interactions |
ISO |
5 |
5,197,891 |
5,275,776 |
RGD:6480464 |
CTD |
| G |
Ncoa3 |
nuclear receptor coactivator 3 |
|
multiple interactions |
ISO |
3 |
157,168,492 |
157,196,566 |
RGD:6480464 |
CTD |
| G |
Ncoa4 |
nuclear receptor coactivator 4 |
|
multiple interactions |
ISO |
16 |
7,642,116 |
7,662,460 |
RGD:6480464 |
CTD |
| G |
Ncoa4 |
nuclear receptor coactivator 4 |
|
multiple interactions |
ISO |
16 |
7,642,116 |
7,662,460 |
RGD:6480464 |
CTD |
| G |
Ncor1 |
nuclear receptor co-repressor 1 |
|
multiple interactions |
ISO |
10 |
48,481,110 |
48,628,538 |
RGD:6480464 |
CTD |
| G |
Ncor1 |
nuclear receptor co-repressor 1 |
|
multiple interactions |
ISO |
10 |
48,481,110 |
48,628,538 |
RGD:6480464 |
CTD |
| G |
Ncor2 |
nuclear receptor co-repressor 2 |
|
multiple interactions |
ISO |
12 |
32,617,643 |
32,725,753 |
RGD:6480464 |
CTD |
| G |
Ncor2 |
nuclear receptor co-repressor 2 |
|
multiple interactions |
ISO |
12 |
32,617,643 |
32,725,753 |
RGD:6480464 |
CTD |
| G |
Nkx3-1 |
NK3 homeobox 1 |
|
decreases expression |
ISO |
15 |
49,743,313 |
49,745,905 |
RGD:6480464 |
CTD |
| G |
Nkx3-1 |
NK3 homeobox 1 |
|
increases expression |
ISO |
15 |
49,743,313 |
49,745,905 |
RGD:6480464 |
CTD |
| G |
Nkx3-1 |
NK3 homeobox 1 |
|
multiple interactions |
ISO |
15 |
49,743,313 |
49,745,905 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
EXP |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
affects binding |
ISO |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
multiple interactions |
ISO |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nts |
neurotensin |
|
affects expression |
ISO |
7 |
40,474,654 |
40,484,058 |
RGD:6480464 |
CTD |
| G |
Nucb1 |
nucleobindin 1 |
|
decreases expression |
ISO |
1 |
95,961,163 |
95,981,910 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
increases expression |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Pa2g4 |
proliferation-associated 2G4 |
|
increases expression |
ISO |
7 |
1,846,628 |
1,854,096 |
RGD:6480464 |
CTD |
| G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
|
affects expression |
EXP |
3 |
108,216,414 |
108,240,138 |
RGD:6480464 |
CTD |
| G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
|
multiple interactions |
EXP |
3 |
108,216,414 |
108,240,138 |
RGD:6480464 |
CTD |
| G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
|
decreases expression |
ISO |
4 |
75,929,398 |
75,948,299 |
RGD:6480464 |
CTD |
| G |
Pea15 |
phosphoprotein enriched in astrocytes 15 |
|
increases expression |
ISO |
13 |
88,187,674 |
88,197,296 |
RGD:6480464 |
CTD |
| G |
Pelp1 |
proline, glutamate and leucine rich protein 1 |
|
multiple interactions |
ISO |
10 |
57,220,324 |
57,237,359 |
RGD:6480464 |
CTD |
| G |
Phb |
prohibitin |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
|
increases expression |
ISO |
X |
58,911,144 |
59,168,857 |
RGD:6480464 |
CTD |
| G |
Phgdh |
phosphoglycerate dehydrogenase |
|
increases expression |
ISO |
2 |
193,147,943 |
193,177,137 |
RGD:6480464 |
CTD |
| G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
|
increases expression |
ISO |
7 |
50,541,011 |
50,543,215 |
RGD:6480464 |
CTD |
| G |
Phospho2 |
phosphatase, orphan 2 |
|
increases expression |
ISO |
3 |
51,937,823 |
51,944,984 |
RGD:6480464 |
CTD |
| G |
Pigf |
phosphatidylinositol glycan anchor biosynthesis, class F |
|
increases expression |
ISO |
6 |
10,446,734 |
10,474,805 |
RGD:6480464 |
CTD |
| G |
Pim1 |
pim-1 oncogene |
|
decreases expression |
ISO |
20 |
7,817,403 |
7,821,800 |
RGD:6480464 |
CTD |
| G |
Pip |
prolactin induced protein |
|
multiple interactions |
ISO |
4 |
69,633,474 |
69,637,768 |
RGD:6480464 |
CTD |
| G |
Pip |
prolactin induced protein |
|
increases expression |
ISO |
4 |
69,633,474 |
69,637,768 |
RGD:6480464 |
CTD |
| G |
Pltp |
phospholipid transfer protein |
|
decreases expression |
ISO |
3 |
155,871,842 |
155,889,959 |
RGD:6480464 |
CTD |
| G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
|
increases expression |
ISO |
3 |
164,094,654 |
164,140,142 |
RGD:6480464 |
CTD |
| G |
Postn |
periostin, osteoblast specific factor |
|
decreases expression |
ISO |
2 |
143,537,099 |
143,568,341 |
RGD:6480464 |
CTD |
| G |
Pou2f1 |
POU class 2 homeobox 1 |
|
decreases expression |
ISO |
13 |
81,607,326 |
81,739,958 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
|
decreases expression |
ISO |
6 |
95,162,067 |
95,198,936 |
RGD:6480464 |
CTD |
| G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
multiple interactions |
ISO |
2 |
54,327,821 |
54,360,462 |
RGD:6480464 |
CTD |
| G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
decreases phosphorylation |
ISO |
2 |
54,327,821 |
54,360,462 |
RGD:6480464 |
CTD |
| G |
Prkaa2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
|
decreases phosphorylation |
ISO |
5 |
126,007,672 |
126,074,012 |
RGD:6480464 |
CTD |
| G |
Prkaa2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
|
multiple interactions |
ISO |
5 |
126,007,672 |
126,074,012 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases abundance |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prnp |
prion protein |
|
decreases expression |
ISO |
3 |
119,676,137 |
119,691,507 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Pthlh |
parathyroid hormone-like hormone |
|
decreases expression |
ISO |
4 |
184,887,702 |
184,898,841 |
RGD:6480464 |
CTD |
| G |
Pts |
6-pyruvoyl-tetrahydropterin synthase |
|
increases expression |
ISO |
8 |
53,880,701 |
53,887,711 |
RGD:6480464 |
CTD |
| G |
Pura |
purine rich element binding protein A |
|
increases expression |
ISO |
18 |
28,916,722 |
28,925,008 |
RGD:6480464 |
CTD |
| G |
Rab7a |
RAB7A, member RAS oncogene family |
|
multiple interactions |
EXP |
4 |
122,202,685 |
122,220,649 |
RGD:6480464 |
CTD |
| G |
Rab7a |
RAB7A, member RAS oncogene family |
|
affects expression |
EXP |
4 |
122,202,685 |
122,220,649 |
RGD:6480464 |
CTD |
| G |
Rad21 |
RAD21 homolog (S. pombe) |
|
increases expression |
ISO |
7 |
88,267,648 |
88,294,703 |
RGD:6480464 |
CTD |
| G |
Rad23b |
RAD23 homolog B (S. cerevisiae) |
|
decreases expression |
ISO |
5 |
73,256,542 |
73,294,296 |
RGD:6480464 |
CTD |
| G |
Rad50 |
RAD50 homolog (S. cerevisiae) |
|
decreases expression |
ISO |
10 |
39,112,733 |
39,164,694 |
RGD:6480464 |
CTD |
| G |
Rarg |
retinoic acid receptor, gamma |
|
increases expression |
ISO |
7 |
140,991,447 |
141,014,108 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
decreases phosphorylation |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
increases phosphorylation |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
RGD1565616 |
RGD1565616 |
|
increases expression |
ISO |
3 |
118,334,338 |
118,467,517 |
RGD:6480464 |
CTD |
| G |
Rora |
RAR-related orphan receptor A |
|
multiple interactions |
ISO |
8 |
73,052,282 |
73,817,764 |
RGD:6480464 |
CTD |
| G |
Rora |
RAR-related orphan receptor A |
|
decreases expression |
ISO |
8 |
73,052,282 |
73,817,764 |
RGD:6480464 |
CTD |
| G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
|
multiple interactions |
EXP |
10 |
76,657,024 |
76,698,088 |
RGD:6480464 |
CTD |
| G |
Rps7 |
ribosomal protein S7 |
|
multiple interactions |
EXP |
6 |
46,511,961 |
46,516,825 |
RGD:6480464 |
CTD |
| G |
Rps7 |
ribosomal protein S7 |
|
affects expression |
EXP |
6 |
46,511,961 |
46,516,825 |
RGD:6480464 |
CTD |
| G |
S100a11 |
S100 calcium binding protein A11 |
|
increases expression |
ISO |
2 |
186,620,360 |
186,621,911 |
RGD:6480464 |
CTD |
| G |
Sar1a |
SAR1 homolog A (S. cerevisiae) |
|
affects expression |
EXP |
20 |
29,048,217 |
29,060,624 |
RGD:6480464 |
CTD |
| G |
Sar1a |
SAR1 homolog A (S. cerevisiae) |
|
multiple interactions |
EXP |
20 |
29,048,217 |
29,060,624 |
RGD:6480464 |
CTD |
| G |
Sdc3 |
syndecan 3 |
|
decreases expression |
ISO |
5 |
149,486,028 |
149,518,849 |
RGD:6480464 |
CTD |
| G |
Selenbp1 |
selenium binding protein 1 |
|
increases expression |
ISO |
2 |
189,840,450 |
189,881,332 |
RGD:6480464 |
CTD |
| G |
Serpinb6 |
serpin peptidase inhibitor, clade B (ovalbumin), member 6 |
|
decreases expression |
ISO |
17 |
37,316,389 |
37,335,124 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
ISO |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Shbg |
sex hormone binding globulin |
|
multiple interactions |
ISO |
10 |
56,432,474 |
56,435,654 |
RGD:6480464 |
CTD |
| G |
Shbg |
sex hormone binding globulin |
|
multiple interactions |
EXP |
10 |
56,432,474 |
56,435,654 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases expression |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc45a3 |
solute carrier family 45, member 3 |
|
increases expression |
ISO |
13 |
44,840,555 |
44,861,173 |
RGD:6480464 |
CTD |
| G |
Slc45a3 |
solute carrier family 45, member 3 |
|
multiple interactions |
ISO |
13 |
44,840,555 |
44,861,173 |
RGD:6480464 |
CTD |
| G |
Smad3 |
SMAD family member 3 |
|
increases expression |
ISO |
8 |
67,803,909 |
67,952,056 |
RGD:6480464 |
CTD |
| G |
Smad4 |
SMAD family member 4 |
|
decreases expression |
ISO |
18 |
70,432,705 |
70,461,541 |
RGD:6480464 |
CTD |
| G |
Smarca2 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
|
multiple interactions |
ISO |
1 |
230,015,057 |
230,183,451 |
RGD:6480464 |
CTD |
| G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
|
multiple interactions |
ISO |
8 |
20,720,915 |
20,812,157 |
RGD:6480464 |
CTD |
| G |
Sms |
spermine synthase |
|
increases expression |
ISO |
X |
58,816,210 |
58,870,980 |
RGD:6480464 |
CTD |
| G |
Snai1 |
snail family zinc finger 1 |
|
increases expression |
ISO |
3 |
158,676,980 |
158,681,471 |
RGD:6480464 |
CTD |
| G |
Snai2 |
snail family zinc finger 2 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
decreases activity |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Spa17 |
sperm autoantigenic protein 17 |
|
increases expression |
ISO |
8 |
38,843,007 |
38,852,080 |
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
increases activity |
ISO |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
EXP |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Srd5a1 |
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) |
|
affects expression |
EXP |
17 |
3,845,190 |
3,879,165 |
RGD:6480464 |
CTD |
| G |
Srd5a2 |
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) |
|
multiple interactions |
ISO |
6 |
21,453,521 |
21,489,408 |
RGD:6480464 |
CTD |
| G |
Srd5a2 |
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) |
|
increases expression |
ISO |
6 |
21,453,521 |
21,489,408 |
RGD:6480464 |
CTD |
| G |
Srd5a2 |
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) |
|
increases expression |
EXP |
6 |
21,453,521 |
21,489,408 |
RGD:6480464 |
CTD |
| G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
|
increases expression |
ISO |
10 |
46,461,684 |
46,483,646 |
RGD:6480464 |
CTD |
| G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
|
increases expression |
ISO |
7 |
120,522,511 |
120,580,212 |
RGD:6480464 |
CTD |
| G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
|
increases expression |
ISO |
7 |
120,522,511 |
120,580,212 |
RGD:6480464 |
CTD |
| G |
Ssrp1 |
structure specific recognition protein 1 |
|
increases expression |
ISO |
3 |
68,272,947 |
68,282,596 |
RGD:6480464 |
CTD |
| G |
Star |
steroidogenic acute regulatory protein |
|
decreases expression |
ISO |
16 |
70,642,580 |
70,647,203 |
RGD:6480464 |
CTD |
| G |
Stk39 |
serine threonine kinase 39 |
|
increases expression |
ISO |
3 |
50,249,626 |
50,517,085 |
RGD:6480464 |
CTD |
| G |
Stk39 |
serine threonine kinase 39 |
|
multiple interactions |
ISO |
3 |
50,249,626 |
50,517,085 |
RGD:6480464 |
CTD |
| G |
Stx2 |
syntaxin 2 |
|
decreases expression |
ISO |
12 |
28,751,591 |
28,773,351 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
multiple interactions |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Thbs1 |
thrombospondin 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Thoc4 |
THO complex 4 |
|
increases expression |
ISO |
10 |
109,984,500 |
109,988,263 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
multiple interactions |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
|
increases expression |
ISO |
9 |
47,519,306 |
47,811,472 |
RGD:6480464 |
CTD |
| G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
|
multiple interactions |
ISO |
9 |
47,519,306 |
47,811,472 |
RGD:6480464 |
CTD |
| G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
|
multiple interactions |
ISO |
9 |
47,519,306 |
47,811,472 |
RGD:6480464 |
CTD |
| G |
Tmprss2 |
transmembrane protease, serine 2 |
|
multiple interactions |
ISO |
11 |
37,577,051 |
37,617,258 |
RGD:6480464 |
CTD |
| G |
Tmprss2 |
transmembrane protease, serine 2 |
|
multiple interactions |
ISO |
11 |
37,577,051 |
37,617,258 |
RGD:6480464 |
CTD |
| G |
Tmprss2 |
transmembrane protease, serine 2 |
|
decreases expression |
ISO |
11 |
37,577,051 |
37,617,258 |
RGD:6480464 |
CTD |
| G |
Tmprss2 |
transmembrane protease, serine 2 |
|
increases expression |
ISO |
11 |
37,577,051 |
37,617,258 |
RGD:6480464 |
CTD |
| G |
Tmsb4x |
thymosin beta 4, X-linked |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tmsb4x |
thymosin beta 4, X-linked |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases response to substance |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b |
|
decreases expression |
ISO |
7 |
90,606,424 |
90,634,431 |
RGD:6480464 |
CTD |
| G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b |
|
multiple interactions |
ISO |
7 |
90,606,424 |
90,634,431 |
RGD:6480464 |
CTD |
| G |
Tob1 |
transducer of ErbB-2.1 |
|
decreases expression |
ISO |
10 |
82,852,405 |
82,854,443 |
RGD:6480464 |
CTD |
| G |
Top2b |
topoisomerase (DNA) II beta |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tpo |
thyroid peroxidase |
|
increases expression |
ISO |
6 |
47,954,848 |
48,025,740 |
RGD:6480464 |
CTD |
| G |
Trap1 |
TNF receptor-associated protein 1 |
|
increases expression |
ISO |
10 |
11,728,524 |
11,762,571 |
RGD:6480464 |
CTD |
| G |
Triobp |
TRIO and F-actin binding protein |
|
increases expression |
ISO |
7 |
116,917,008 |
116,969,695 |
RGD:6480464 |
CTD |
| G |
Tsc2 |
tuberous sclerosis 2 |
|
multiple interactions |
EXP |
10 |
13,848,210 |
13,883,189 |
RGD:6480464 |
CTD |
| G |
Tsg101 |
tumor susceptibility gene 101 |
|
decreases expression |
ISO |
1 |
97,445,040 |
97,475,141 |
RGD:6480464 |
CTD |
| G |
Tubb4a |
tubulin, beta 4A class IVa |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ufm1 |
ubiquitin-fold modifier 1 |
|
increases expression |
ISO |
2 |
143,057,364 |
143,064,329 |
RGD:6480464 |
CTD |
| G |
Ugt2b15 |
UDP glucuronosyltransferase 2 family, polypeptide B15 |
|
increases expression |
ISO |
14 |
22,346,334 |
22,366,860 |
RGD:6480464 |
CTD |
| G |
Ugt2b15 |
UDP glucuronosyltransferase 2 family, polypeptide B15 |
|
increases glucuronidation |
ISO |
14 |
22,346,334 |
22,366,860 |
RGD:6480464 |
CTD |
| G |
Ugt2b15 |
UDP glucuronosyltransferase 2 family, polypeptide B15 |
|
multiple interactions |
ISO |
14 |
22,346,334 |
22,366,860 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
increases metabolic processing |
ISO |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
increases glucuronidation |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
multiple interactions |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
increases expression |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
increases glucuronidation |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
increases glucuronidation |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
ISO |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vmp1 |
vacuole membrane protein 1 |
|
increases expression |
ISO |
10 |
74,865,123 |
74,964,158 |
RGD:6480464 |
CTD |
| G |
Wbscr28 |
Williams-Beuren syndrome chromosome region 28 |
|
decreases expression |
ISO |
12 |
22,858,647 |
22,863,206 |
RGD:6480464 |
CTD |
| G |
Ywhah |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide |
|
increases expression |
ISO |
14 |
83,448,395 |
83,457,778 |
RGD:6480464 |
CTD |
| G |
Zbtb26 |
zinc finger and BTB domain containing 26 |
|
increases expression |
ISO |
3 |
17,194,711 |
17,204,723 |
RGD:6480464 |
CTD |
| G |
Zfhx3 |
zinc finger homeobox 3 |
|
decreases expression |
ISO |
19 |
38,547,428 |
38,783,613 |
RGD:6480464 |
CTD |
androst-4-ene-3,17-dione
|
| G |
Abcg5 |
ATP-binding cassette, subfamily G (WHITE), member 5 |
|
multiple interactions |
ISO |
6 |
8,027,647 |
8,064,425 |
RGD:6480464 |
CTD |
| G |
Abcg8 |
ATP-binding cassette, subfamily G (WHITE), member 8 |
|
multiple interactions |
ISO |
6 |
8,064,631 |
8,083,271 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
increases metabolic processing |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
increases reduction |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
increases reduction |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Crebbp |
CREB binding protein |
|
increases activity |
ISO |
10 |
11,598,680 |
11,724,122 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
affects chemical synthesis |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
decreases expression |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
affects abundance |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
affects chemical synthesis |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
affects chemical synthesis |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
affects chemical synthesis |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
affects chemical synthesis |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases metabolic processing |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
decreases expression |
ISO |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
increases expression |
ISO |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
|
increases expression |
ISO |
1 |
81,084,984 |
81,185,251 |
RGD:6480464 |
CTD |
| G |
Gsta2 |
glutathione S-transferase alpha 2 |
|
decreases metabolic processing |
ISO |
8 |
83,299,249 |
83,312,958 |
RGD:6480464 |
CTD |
| G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
|
increases metabolic processing |
ISO |
3 |
78,436,634 |
78,559,707 |
RGD:6480464 |
CTD |
| G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
|
increases chemical synthesis |
ISO |
19 |
47,729,519 |
47,802,933 |
RGD:6480464 |
CTD |
| G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
|
increases metabolic processing |
ISO |
17 |
6,554,164 |
6,585,525 |
RGD:6480464 |
CTD |
| G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
|
increases chemical synthesis |
ISO |
2 |
193,337,342 |
193,346,799 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
multiple interactions |
ISO |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
affects activity |
ISO |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
multiple interactions |
ISO |
6 |
27,224,396 |
27,473,926 |
RGD:6480464 |
CTD |
| G |
Ncoa2 |
nuclear receptor coactivator 2 |
|
multiple interactions |
ISO |
5 |
5,197,891 |
5,275,776 |
RGD:6480464 |
CTD |
| G |
Ncoa3 |
nuclear receptor coactivator 3 |
|
increases activity |
ISO |
3 |
157,168,492 |
157,196,566 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
decreases activity |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
decreases activity |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
decreases activity |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
|
increases expression |
EXP |
13 |
49,931,592 |
50,048,756 |
RGD:6480464 |
CTD |
| G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
|
multiple interactions |
EXP |
13 |
49,931,592 |
50,048,756 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
corticosterone
|
| G |
A2m |
alpha-2-macroglobulin |
|
increases expression |
EXP |
4 |
158,103,711 |
158,153,423 |
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
decreases activity |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Acaca |
acetyl-CoA carboxylase alpha |
|
multiple interactions |
EXP |
10 |
72,483,772 |
72,677,134 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
increases expression |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Acly |
ATP citrate lyase |
|
multiple interactions |
EXP |
10 |
89,420,934 |
89,471,398 |
RGD:6480464 |
CTD |
| G |
Acta1 |
actin, alpha 1, skeletal muscle |
|
increases expression |
EXP |
19 |
54,081,496 |
54,084,508 |
RGD:6480464 |
CTD |
| G |
Actg2 |
actin, gamma 2, smooth muscle, enteric |
|
increases expression |
EXP |
4 |
117,732,482 |
117,747,006 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
increases expression |
EXP |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Adm |
adrenomedullin |
|
increases expression |
EXP |
1 |
168,380,255 |
168,382,426 |
RGD:6480464 |
CTD |
| G |
Adrb2 |
adrenoceptor beta 2, surface |
|
increases expression |
EXP |
18 |
58,174,958 |
58,177,000 |
RGD:6480464 |
CTD |
| G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
|
decreases expression |
EXP |
1 |
245,685,979 |
245,718,198 |
RGD:6480464 |
CTD |
| G |
Angptl2 |
angiopoietin-like 2 |
|
decreases expression |
EXP |
3 |
12,226,515 |
12,256,396 |
RGD:6480464 |
CTD |
| G |
Aqp1 |
aquaporin 1 |
|
increases expression |
EXP |
4 |
84,098,346 |
84,110,524 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Arrb1 |
arrestin, beta 1 |
|
decreases expression |
ISO |
1 |
156,871,564 |
156,937,540 |
RGD:6480464 |
CTD |
| G |
Arrb1 |
arrestin, beta 1 |
|
multiple interactions |
ISO |
1 |
156,871,564 |
156,937,540 |
RGD:6480464 |
CTD |
| G |
Arrb2 |
arrestin, beta 2 |
|
decreases expression |
ISO |
10 |
57,244,071 |
57,284,166 |
RGD:6480464 |
CTD |
| G |
Arrb2 |
arrestin, beta 2 |
|
multiple interactions |
ISO |
10 |
57,244,071 |
57,284,166 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
decreases expression |
EXP |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Atp1a3 |
ATPase, Na+/K+ transporting, alpha 3 polypeptide |
|
decreases expression |
EXP |
1 |
80,280,714 |
80,309,834 |
RGD:6480464 |
CTD |
| G |
Atp6v1g1 |
ATPase, H transporting, lysosomal V1 subunit G1 |
|
decreases expression |
EXP |
5 |
80,515,635 |
80,521,815 |
RGD:6480464 |
CTD |
| G |
Aurkb |
aurora kinase B |
|
decreases expression |
EXP |
10 |
55,798,710 |
55,804,367 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bex1 |
brain expressed, X-linked 1 |
|
decreases expression |
EXP |
X |
123,527,737 |
123,529,133 |
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
increases expression |
EXP |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Bmp6 |
bone morphogenetic protein 6 |
|
increases expression |
EXP |
17 |
32,380,199 |
32,689,295 |
RGD:6480464 |
CTD |
| G |
Btg2 |
BTG family, member 2 |
|
increases expression |
EXP |
13 |
47,026,986 |
47,030,745 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
increases abundance |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Capn6 |
calpain 6 |
|
decreases expression |
EXP |
X |
34,697,658 |
34,722,369 |
RGD:6480464 |
CTD |
| G |
Cars |
cysteinyl-tRNA synthetase |
|
decreases expression |
EXP |
1 |
203,934,812 |
203,977,042 |
RGD:6480464 |
CTD |
| G |
Cartpt |
CART prepropeptide |
|
increases abundance |
EXP |
2 |
30,889,817 |
30,891,837 |
RGD:6480464 |
CTD |
| G |
Cartpt |
CART prepropeptide |
|
multiple interactions |
EXP |
2 |
30,889,817 |
30,891,837 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
decreases expression |
EXP |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
|
decreases expression |
EXP |
8 |
2,038,626 |
2,075,722 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
EXP |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd2 |
cyclin D2 |
|
decreases expression |
EXP |
4 |
163,523,817 |
163,546,501 |
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
decreases expression |
EXP |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Cd200 |
Cd200 molecule |
|
decreases expression |
EXP |
11 |
56,946,504 |
56,974,256 |
RGD:6480464 |
CTD |
| G |
Cd59 |
CD59 molecule, complement regulatory protein |
|
increases expression |
EXP |
3 |
89,243,600 |
89,245,129 |
RGD:6480464 |
CTD |
| G |
Cdc20 |
cell division cycle 20 |
|
decreases expression |
EXP |
5 |
138,913,180 |
138,916,744 |
RGD:6480464 |
CTD |
| G |
Cdh2 |
cadherin 2 |
|
multiple interactions |
ISO |
18 |
8,048,920 |
8,267,974 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
decreases expression |
EXP |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
multiple interactions |
EXP |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases expression |
EXP |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases activity |
EXP |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
affects expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
multiple interactions |
EXP |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
EXP |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
decreases expression |
EXP |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Cdo1 |
cysteine dioxygenase, type I |
|
increases expression |
EXP |
18 |
40,914,028 |
40,928,671 |
RGD:6480464 |
CTD |
| G |
Ceacam10 |
carcinoembryonic antigen-related cell adhesion molecule 10 |
|
increases expression |
EXP |
1 |
80,070,252 |
80,076,528 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
increases expression |
EXP |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpd |
CCAAT/enhancer binding protein (C/EBP), delta |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
|
decreases expression |
EXP |
17 |
19,423,502 |
19,429,451 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
increases abundance |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
increases expression |
EXP |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
|
increases expression |
EXP |
1 |
205,852,800 |
205,912,972 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
multiple interactions |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
increases abundance |
ISO |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
affects expression |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
multiple interactions |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
|
decreases expression |
EXP |
10 |
93,312,405 |
93,354,229 |
RGD:6480464 |
CTD |
| G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
|
increases expression |
EXP |
19 |
50,313,710 |
50,378,031 |
RGD:6480464 |
CTD |
| G |
Csrp2 |
cysteine and glycine-rich protein 2 |
|
increases expression |
EXP |
7 |
49,910,235 |
49,929,536 |
RGD:6480464 |
CTD |
| G |
Csrp3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
increases expression |
EXP |
1 |
98,601,681 |
98,611,747 |
RGD:6480464 |
CTD |
| G |
Ctnna1 |
catenin (cadherin-associated protein), alpha 1, 102kDa |
|
multiple interactions |
ISO |
18 |
27,629,915 |
27,769,360 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctss |
cathepsin S |
|
increases expression |
EXP |
2 |
190,425,290 |
190,466,877 |
RGD:6480464 |
CTD |
| G |
Cyp11b1 |
cytochrome P450, family 11, subfamily b, polypeptide 1 |
|
increases chemical synthesis |
ISO |
7 |
112,977,395 |
112,984,080 |
RGD:6480464 |
CTD |
| G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
|
affects metabolic processing |
ISO |
7 |
113,043,365 |
113,049,779 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases expression |
EXP |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases metabolic processing |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Dbi |
diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Dcxr |
dicarbonyl L-xylulose reductase |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
decreases expression |
EXP |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Ddt |
D-dopachrome tautomerase |
|
increases expression |
EXP |
20 |
13,591,785 |
13,594,256 |
RGD:6480464 |
CTD |
| G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
|
multiple interactions |
ISO |
1 |
234,392,743 |
234,396,426 |
RGD:6480464 |
CTD |
| G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
|
increases expression |
ISO |
1 |
234,392,743 |
234,396,426 |
RGD:6480464 |
CTD |
| G |
Dpep1 |
dipeptidase 1 (renal) |
|
increases expression |
EXP |
19 |
53,503,467 |
53,518,440 |
RGD:6480464 |
CTD |
| G |
Dpt |
dermatopontin |
|
decreases expression |
EXP |
13 |
80,562,890 |
80,591,361 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
increases secretion |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn2 |
endothelin 2 |
|
increases secretion |
EXP |
5 |
140,742,686 |
140,747,580 |
RGD:6480464 |
CTD |
| G |
Edn3 |
endothelin 3 |
|
increases secretion |
EXP |
3 |
166,491,368 |
166,514,051 |
RGD:6480464 |
CTD |
| G |
Eef2k |
eukaryotic elongation factor-2 kinase |
|
increases expression |
EXP |
1 |
179,712,404 |
179,754,345 |
RGD:6480464 |
CTD |
| G |
Efemp1 |
EGF-containing fibulin-like extracellular matrix protein 1 |
|
increases expression |
EXP |
14 |
109,733,625 |
109,828,630 |
RGD:6480464 |
CTD |
| G |
Egln3 |
EGL nine homolog 3 (C. elegans) |
|
increases expression |
EXP |
6 |
74,451,038 |
74,476,506 |
RGD:6480464 |
CTD |
| G |
Ezh2 |
enhancer of zeste homolog 2 (Drosophila) |
|
decreases expression |
EXP |
4 |
75,709,959 |
75,773,279 |
RGD:6480464 |
CTD |
| G |
Fabp3 |
fatty acid binding protein 3, muscle and heart |
|
decreases expression |
EXP |
5 |
149,340,525 |
149,347,268 |
RGD:6480464 |
CTD |
| G |
Fabp7 |
fatty acid binding protein 7, brain |
|
affects expression |
EXP |
20 |
36,812,518 |
36,816,050 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Fbln2 |
fibulin 2 |
|
decreases expression |
EXP |
4 |
125,380,549 |
125,441,079 |
RGD:6480464 |
CTD |
| G |
Fbn2 |
fibrillin 2 |
|
increases expression |
EXP |
18 |
53,883,011 |
53,914,001 |
RGD:6480464 |
CTD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
increases expression |
EXP |
12 |
7,858,092 |
8,035,966 |
RGD:6480464 |
CTD |
| G |
Fmo1 |
flavin containing monooxygenase 1 |
|
increases expression |
EXP |
13 |
78,503,770 |
78,536,359 |
RGD:6480464 |
CTD |
| G |
Foxs1 |
forkhead box S1 |
|
decreases expression |
EXP |
3 |
143,272,507 |
143,273,776 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
increases expression |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fstl3 |
follistatin-like 3 (secreted glycoprotein) |
|
increases expression |
EXP |
7 |
11,438,360 |
11,442,885 |
RGD:6480464 |
CTD |
| G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
|
decreases expression |
EXP |
8 |
48,323,818 |
48,371,958 |
RGD:6480464 |
CTD |
| G |
Gad1 |
glutamate decarboxylase 1 |
|
multiple interactions |
ISO |
3 |
52,789,370 |
52,830,038 |
RGD:6480464 |
CTD |
| G |
Gal |
galanin/GMAP prepropeptide |
|
increases expression |
EXP |
1 |
205,936,352 |
205,941,215 |
RGD:6480464 |
CTD |
| G |
Gas6 |
growth arrest specific 6 |
|
increases expression |
EXP |
16 |
80,900,159 |
80,930,929 |
RGD:6480464 |
CTD |
| G |
Gatm |
glycine amidinotransferase (L-arginine:glycine amidinotransferase) |
|
decreases expression |
EXP |
3 |
109,558,043 |
109,565,432 |
RGD:6480464 |
CTD |
| G |
Gcnt1 |
glucosaminyl (N-acetyl) transferase 1, core 2 |
|
increases expression |
EXP |
1 |
220,824,976 |
220,829,980 |
RGD:6480464 |
CTD |
| G |
Gja5 |
gap junction protein, alpha 5 |
|
increases expression |
EXP |
2 |
191,824,118 |
191,843,867 |
RGD:6480464 |
CTD |
| G |
Glt8d1 |
glycosyltransferase 8 domain containing 1 |
|
decreases expression |
EXP |
16 |
6,429,357 |
6,444,262 |
RGD:6480464 |
CTD |
| G |
Glul |
glutamate-ammonia ligase |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Gnai2 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 |
|
decreases expression |
ISO |
8 |
112,861,952 |
112,882,647 |
RGD:6480464 |
CTD |
| G |
Gnai2 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 |
|
multiple interactions |
ISO |
8 |
112,861,952 |
112,882,647 |
RGD:6480464 |
CTD |
| G |
Gpx3 |
glutathione peroxidase 3 |
|
increases expression |
EXP |
10 |
40,311,094 |
40,319,382 |
RGD:6480464 |
CTD |
| G |
Grem1 |
gremlin 1 |
|
decreases expression |
EXP |
3 |
99,597,201 |
99,608,935 |
RGD:6480464 |
CTD |
| G |
Grk5 |
G protein-coupled receptor kinase 5 |
|
increases expression |
EXP |
1 |
267,495,534 |
267,693,144 |
RGD:6480464 |
CTD |
| G |
Gsta3 |
glutathione S-transferase alpha 3 |
|
increases expression |
EXP |
9 |
20,005,570 |
20,032,031 |
RGD:6480464 |
CTD |
| G |
Gstm2 |
glutathione S-transferase mu 2 |
|
increases expression |
EXP |
2 |
203,549,022 |
203,553,380 |
RGD:6480464 |
CTD |
| G |
Hmgb2 |
high mobility group box 2 |
|
decreases expression |
EXP |
16 |
36,131,304 |
36,133,878 |
RGD:6480464 |
CTD |
| G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) |
|
increases expression |
EXP |
2 |
193,128,736 |
193,143,106 |
RGD:6480464 |
CTD |
| G |
Hs3st1 |
heparan sulfate (glucosamine) 3-O-sulfotransferase 1 |
|
increases expression |
EXP |
14 |
76,438,219 |
76,439,157 |
RGD:6480464 |
CTD |
| G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
|
increases chemical synthesis |
ISO |
13 |
109,063,491 |
109,089,468 |
RGD:6480464 |
CTD |
| G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
|
increases expression |
EXP |
13 |
109,063,491 |
109,089,468 |
RGD:6480464 |
CTD |
| G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
|
multiple interactions |
EXP |
19 |
35,336,342 |
35,341,585 |
RGD:6480464 |
CTD |
| G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
|
affects metabolic processing |
EXP |
19 |
35,336,342 |
35,341,585 |
RGD:6480464 |
CTD |
| G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
|
increases metabolic processing |
ISO |
19 |
35,336,342 |
35,341,585 |
RGD:6480464 |
CTD |
| G |
Hspb1 |
heat shock protein 1 |
|
increases expression |
EXP |
12 |
21,911,223 |
21,912,784 |
RGD:6480464 |
CTD |
| G |
Hspb6 |
heat shock protein, alpha-crystallin-related, B6 |
|
increases expression |
EXP |
1 |
85,599,075 |
85,601,214 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
increases expression |
EXP |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
multiple interactions |
EXP |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
increases expression |
EXP |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
increases expression |
EXP |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
increases secretion |
EXP |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled |
|
multiple interactions |
EXP |
15 |
55,463,743 |
55,532,293 |
RGD:6480464 |
CTD |
| G |
Ier3 |
immediate early response 3 |
|
decreases expression |
EXP |
20 |
3,076,568 |
3,077,772 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
decreases expression |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases expression |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
decreases expression |
EXP |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
|
decreases expression |
EXP |
9 |
72,003,637 |
72,016,263 |
RGD:6480464 |
CTD |
| G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
|
increases expression |
EXP |
7 |
140,885,388 |
140,890,028 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
increases expression |
EXP |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases chemical synthesis |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1rl1 |
interleukin 1 receptor-like 1 |
|
decreases expression |
EXP |
9 |
39,577,879 |
39,624,781 |
RGD:6480464 |
CTD |
| G |
Irs3 |
insulin receptor substrate 3 |
|
increases expression |
EXP |
12 |
19,709,141 |
19,711,279 |
RGD:6480464 |
CTD |
| G |
Itga1 |
integrin, alpha 1 |
|
decreases expression |
EXP |
2 |
47,107,849 |
47,206,261 |
RGD:6480464 |
CTD |
| G |
Itga8 |
integrin, alpha 8 |
|
increases expression |
EXP |
17 |
86,427,191 |
86,649,268 |
RGD:6480464 |
CTD |
| G |
Itgb1bp2 |
integrin beta 1 binding protein 2 |
|
increases expression |
EXP |
X |
89,520,700 |
89,525,600 |
RGD:6480464 |
CTD |
| G |
Jak2 |
Janus kinase 2 |
|
multiple interactions |
EXP |
1 |
232,915,995 |
232,974,763 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
increases expression |
EXP |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
|
increases expression |
EXP |
8 |
32,082,866 |
32,104,412 |
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Kif15 |
kinesin family member 15 |
|
decreases expression |
EXP |
8 |
127,694,272 |
127,764,633 |
RGD:6480464 |
CTD |
| G |
Kifc1 |
kinesin family member C1 |
|
decreases expression |
EXP |
20 |
5,150,810 |
5,169,264 |
RGD:6480464 |
CTD |
| G |
Klf9 |
Kruppel-like factor 9 |
|
increases expression |
EXP |
1 |
226,420,949 |
226,446,376 |
RGD:6480464 |
CTD |
| G |
Lepre1 |
leucine proline-enriched proteoglycan (leprecan) 1 |
|
decreases expression |
EXP |
5 |
139,816,323 |
139,831,409 |
RGD:6480464 |
CTD |
| G |
Lmnb1 |
lamin B1 |
|
decreases expression |
EXP |
18 |
52,470,605 |
52,508,022 |
RGD:6480464 |
CTD |
| G |
LOC100360316 |
hypothetical protein LOC100360316 |
|
decreases expression |
EXP |
16 |
33,979,260 |
33,979,532 |
RGD:6480464 |
CTD |
| G |
Lpar1 |
lysophosphatidic acid receptor 1 |
|
increases expression |
EXP |
5 |
76,449,470 |
76,571,458 |
RGD:6480464 |
CTD |
| G |
Maged2 |
melanoma antigen, family D, 2 |
|
decreases expression |
EXP |
X |
40,056,332 |
40,064,505 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases activity |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases activity |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mb |
myoglobin |
|
decreases expression |
EXP |
7 |
115,087,558 |
115,094,789 |
RGD:6480464 |
CTD |
| G |
Mcm3 |
minichromosome maintenance complex component 3 |
|
decreases expression |
EXP |
9 |
19,536,922 |
19,554,871 |
RGD:6480464 |
CTD |
| G |
Mcm4 |
minichromosome maintenance complex component 4 |
|
decreases expression |
EXP |
11 |
87,169,742 |
87,183,443 |
RGD:6480464 |
CTD |
| G |
Mcm6 |
minichromosome maintenance complex component 6 |
|
decreases expression |
EXP |
13 |
41,045,677 |
41,070,868 |
RGD:6480464 |
CTD |
| G |
Mcm7 |
minichromosome maintenance complex component 7 |
|
decreases expression |
EXP |
12 |
17,607,250 |
17,614,508 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
decreases expression |
EXP |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Melk |
maternal embryonic leucine zipper kinase |
|
decreases expression |
EXP |
5 |
60,787,123 |
60,848,620 |
RGD:6480464 |
CTD |
| G |
Mgst2 |
microsomal glutathione S-transferase 2 |
|
increases expression |
EXP |
2 |
140,546,939 |
140,568,616 |
RGD:6480464 |
CTD |
| G |
Mmp12 |
matrix metallopeptidase 12 |
|
decreases expression |
EXP |
8 |
4,249,938 |
4,259,675 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
increases expression |
EXP |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
decreases phosphorylation |
ISO |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Mustn1 |
musculoskeletal, embryonic nuclear protein 1 |
|
increases expression |
EXP |
16 |
6,311,978 |
6,314,228 |
RGD:6480464 |
CTD |
| G |
Myh11 |
myosin, heavy chain 11, smooth muscle |
|
increases expression |
EXP |
10 |
666,709 |
776,540 |
RGD:6480464 |
CTD |
| G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
|
decreases expression |
EXP |
4 |
161,288,671 |
161,310,417 |
RGD:6480464 |
CTD |
| G |
Ncaph2 |
non-SMC condensin II complex, subunit H2 |
|
decreases expression |
EXP |
7 |
127,650,768 |
127,666,461 |
RGD:6480464 |
CTD |
| G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
multiple interactions |
ISO |
6 |
27,224,396 |
27,473,926 |
RGD:6480464 |
CTD |
| G |
Ncs1 |
neuronal calcium sensor 1 |
|
increases expression |
ISO |
3 |
10,305,202 |
10,354,149 |
RGD:6480464 |
CTD |
| G |
Ndrg1 |
N-myc downstream regulated 1 |
|
multiple interactions |
ISO |
7 |
104,302,038 |
104,344,842 |
RGD:6480464 |
CTD |
| G |
Ndrg1 |
N-myc downstream regulated 1 |
|
increases phosphorylation |
ISO |
7 |
104,302,038 |
104,344,842 |
RGD:6480464 |
CTD |
| G |
Ndrg2 |
NDRG family member 2 |
|
increases expression |
EXP |
15 |
27,338,552 |
27,347,196 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nov |
nephroblastoma overexpressed |
|
increases expression |
EXP |
7 |
91,162,676 |
91,169,696 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
increases expression |
EXP |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
multiple interactions |
EXP |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
decreases expression |
EXP |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects binding |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects abundance |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
decreases expression |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
affects binding |
ISO |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Ntrk3 |
neurotrophic tyrosine kinase, receptor, type 3 |
|
increases expression |
EXP |
1 |
133,925,530 |
134,302,139 |
RGD:6480464 |
CTD |
| G |
Omd |
osteomodulin |
|
increases expression |
EXP |
17 |
21,015,178 |
21,023,126 |
RGD:6480464 |
CTD |
| G |
Oplah |
5-oxoprolinase (ATP-hydrolysing) |
|
increases expression |
EXP |
7 |
114,326,739 |
114,341,949 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
increases expression |
EXP |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
|
decreases expression |
EXP |
15 |
33,671,834 |
33,680,613 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
decreases expression |
EXP |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pdk1 |
pyruvate dehydrogenase kinase, isozyme 1 |
|
multiple interactions |
ISO |
3 |
54,292,076 |
54,319,242 |
RGD:6480464 |
CTD |
| G |
Pdlim5 |
PDZ and LIM domain 5 |
|
increases expression |
EXP |
2 |
240,177,301 |
240,304,192 |
RGD:6480464 |
CTD |
| G |
Pdlim7 |
PDZ and LIM domain 7 |
|
increases expression |
EXP |
17 |
15,168,835 |
15,183,983 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
multiple interactions |
EXP |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
multiple interactions |
ISO |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Penk |
proenkephalin |
|
multiple interactions |
EXP |
5 |
17,509,323 |
17,514,265 |
RGD:6480464 |
CTD |
| G |
Pfkl |
phosphofructokinase, liver |
|
increases expression |
EXP |
20 |
11,009,359 |
11,032,511 |
RGD:6480464 |
CTD |
| G |
Pfn2 |
profilin 2 |
|
decreases expression |
EXP |
2 |
147,066,815 |
147,072,519 |
RGD:6480464 |
CTD |
| G |
Pim3 |
pim-3 oncogene |
|
increases expression |
EXP |
7 |
127,167,984 |
127,172,018 |
RGD:6480464 |
CTD |
| G |
Pla1a |
phospholipase A1 member A |
|
increases expression |
EXP |
11 |
64,099,837 |
64,137,353 |
RGD:6480464 |
CTD |
| G |
Plk1 |
polo-like kinase 1 |
|
decreases expression |
EXP |
1 |
181,002,811 |
181,012,741 |
RGD:6480464 |
CTD |
| G |
Plk2 |
polo-like kinase 2 |
|
decreases expression |
EXP |
2 |
41,800,745 |
41,806,503 |
RGD:6480464 |
CTD |
| G |
Plk4 |
polo-like kinase 4 |
|
decreases expression |
EXP |
2 |
127,760,508 |
127,779,640 |
RGD:6480464 |
CTD |
| G |
Podxl |
podocalyxin-like |
|
increases expression |
EXP |
4 |
58,611,904 |
58,658,598 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
decreases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
decreases abundance |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
decreases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases abundance |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases abundance |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
|
multiple interactions |
ISO |
10 |
87,121,889 |
87,131,587 |
RGD:6480464 |
CTD |
| G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
|
decreases expression |
EXP |
18 |
35,865,837 |
36,318,308 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
multiple interactions |
ISO |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Pten |
phosphatase and tensin homolog |
|
increases phosphorylation |
ISO |
1 |
236,771,027 |
236,837,261 |
RGD:6480464 |
CTD |
| G |
Ptgds |
prostaglandin D2 synthase (brain) |
|
increases expression |
EXP |
3 |
3,632,683 |
3,635,617 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
increases expression |
EXP |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Pth |
parathyroid hormone |
|
multiple interactions |
EXP |
1 |
171,240,596 |
171,243,528 |
RGD:6480464 |
CTD |
| G |
Ptpn3 |
protein tyrosine phosphatase, non-receptor type 3 |
|
decreases expression |
EXP |
5 |
75,106,880 |
75,222,735 |
RGD:6480464 |
CTD |
| G |
Pttg1 |
pituitary tumor-transforming 1 |
|
decreases expression |
EXP |
10 |
28,527,409 |
28,532,831 |
RGD:6480464 |
CTD |
| G |
Qsox1 |
quiescin Q6 sulfhydryl oxidase 1 |
|
increases expression |
EXP |
13 |
70,739,793 |
70,777,526 |
RGD:6480464 |
CTD |
| G |
Rapgef4 |
Rap guanine nucleotide exchange factor (GEF) 4 |
|
increases expression |
EXP |
3 |
54,396,312 |
54,717,148 |
RGD:6480464 |
CTD |
| G |
Rbp1 |
retinol binding protein 1, cellular |
|
decreases expression |
EXP |
8 |
103,605,870 |
103,627,390 |
RGD:6480464 |
CTD |
| G |
Reg3b |
regenerating islet-derived 3 beta |
|
decreases expression |
EXP |
4 |
112,355,773 |
112,359,011 |
RGD:6480464 |
CTD |
| G |
Retn |
resistin |
|
increases expression |
ISO |
12 |
2,499,630 |
2,501,370 |
RGD:6480464 |
CTD |
| G |
Rfc3 |
replication factor C (activator 1) 3 |
|
decreases expression |
EXP |
12 |
3,224,493 |
3,235,256 |
RGD:6480464 |
CTD |
| G |
Rfc4 |
replication factor C (activator 1) 4 |
|
decreases expression |
EXP |
11 |
79,935,273 |
79,950,589 |
RGD:6480464 |
CTD |
| G |
Rgcc |
regulator of cell cycle |
|
increases expression |
EXP |
15 |
60,451,831 |
60,452,229 |
RGD:6480464 |
CTD |
| G |
RGD1305645 |
similar to RIKEN cDNA 1500015O10 |
|
decreases expression |
EXP |
9 |
42,931,051 |
42,950,605 |
RGD:6480464 |
CTD |
| G |
RGD1562067 |
similar to cell division cycle associated 3 |
|
decreases expression |
EXP |
9 |
43,464,113 |
43,464,928 |
RGD:6480464 |
CTD |
| G |
RGD1562323 |
similar to fatty acid translocase/CD36 |
|
increases expression |
EXP |
4 |
13,534,582 |
13,554,416 |
RGD:6480464 |
CTD |
| G |
Rhoj |
ras homolog family member J |
|
increases expression |
EXP |
6 |
97,911,744 |
97,995,878 |
RGD:6480464 |
CTD |
| G |
Rpa2 |
replication protein A2 |
|
decreases expression |
EXP |
5 |
152,369,550 |
152,380,370 |
RGD:6480464 |
CTD |
| G |
Rrm1-ps1 |
ribonucleotide reductase M1, pseudogene 1 |
|
decreases expression |
EXP |
14 |
77,408,781 |
77,411,150 |
RGD:6480464 |
CTD |
| G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
|
decreases expression |
EXP |
1 |
249,458,860 |
249,471,460 |
RGD:6480464 |
CTD |
| G |
Sdc1 |
syndecan 1 |
|
decreases expression |
EXP |
6 |
32,253,352 |
32,275,812 |
RGD:6480464 |
CTD |
| G |
Sdc2 |
syndecan 2 |
|
decreases expression |
EXP |
7 |
68,290,558 |
68,405,183 |
RGD:6480464 |
CTD |
| G |
Sdc4 |
syndecan 4 |
|
increases expression |
EXP |
3 |
155,446,138 |
155,464,825 |
RGD:6480464 |
CTD |
| G |
Sepp1 |
selenoprotein P, plasma, 1 |
|
increases expression |
EXP |
2 |
52,451,883 |
52,462,263 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
EXP |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
increases expression |
EXP |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
increases expression |
ISO |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
multiple interactions |
ISO |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
increases phosphorylation |
ISO |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
| G |
Slc1a2 |
solute carrier family 1 (glial high affinity glutamate transporter), member 2 |
|
multiple interactions |
ISO |
3 |
87,870,558 |
87,992,401 |
RGD:6480464 |
CTD |
| G |
Slc1a2 |
solute carrier family 1 (glial high affinity glutamate transporter), member 2 |
|
increases expression |
ISO |
3 |
87,870,558 |
87,992,401 |
RGD:6480464 |
CTD |
| G |
Slc1a2 |
solute carrier family 1 (glial high affinity glutamate transporter), member 2 |
|
increases expression |
ISO |
3 |
87,870,558 |
87,992,401 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
decreases activity |
EXP |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
decreases activity |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
EXP |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
EXP |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases expression |
EXP |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
increases expression |
EXP |
10 |
56,786,705 |
56,792,209 |
RGD:6480464 |
CTD |
| G |
Smarcd2 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2 |
|
increases expression |
EXP |
10 |
95,656,976 |
95,665,842 |
RGD:6480464 |
CTD |
| G |
Sorbs2 |
sorbin and SH3 domain containing 2 |
|
increases expression |
EXP |
16 |
49,722,539 |
49,917,550 |
RGD:6480464 |
CTD |
| G |
Sox4 |
SRY (sex determining region Y)-box 4 |
|
decreases expression |
EXP |
17 |
42,172,863 |
42,177,590 |
RGD:6480464 |
CTD |
| G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
|
multiple interactions |
EXP |
10 |
46,461,684 |
46,483,646 |
RGD:6480464 |
CTD |
| G |
Stmn1 |
stathmin 1 |
|
decreases expression |
EXP |
5 |
153,226,420 |
153,232,084 |
RGD:6480464 |
CTD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
increases expression |
EXP |
1 |
185,829,205 |
185,832,725 |
RGD:6480464 |
CTD |
| G |
Tat |
tyrosine aminotransferase |
|
multiple interactions |
EXP |
19 |
39,854,163 |
39,865,060 |
RGD:6480464 |
CTD |
| G |
Tcf21 |
transcription factor 21 |
|
increases expression |
EXP |
1 |
23,211,054 |
23,213,913 |
RGD:6480464 |
CTD |
| G |
Tcp1 |
t-complex 1 |
|
decreases expression |
EXP |
1 |
42,103,543 |
42,111,222 |
RGD:6480464 |
CTD |
| G |
Tdo2 |
tryptophan 2,3-dioxygenase |
|
increases activity |
EXP |
2 |
173,594,020 |
173,611,833 |
RGD:6480464 |
CTD |
| G |
Tf |
transferrin |
|
increases expression |
EXP |
8 |
108,217,774 |
108,244,487 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgm2 |
transglutaminase 2, C polypeptide |
|
increases expression |
EXP |
3 |
148,832,866 |
148,862,385 |
RGD:6480464 |
CTD |
| G |
Tinagl1 |
tubulointerstitial nephritis antigen-like 1 |
|
increases expression |
EXP |
5 |
149,198,274 |
149,207,653 |
RGD:6480464 |
CTD |
| G |
Tk1 |
thymidine kinase 1, soluble |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnc |
tenascin C |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b |
|
decreases expression |
EXP |
7 |
90,606,424 |
90,634,431 |
RGD:6480464 |
CTD |
| G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b |
|
multiple interactions |
EXP |
7 |
90,606,424 |
90,634,431 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
multiple interactions |
EXP |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
increases expression |
EXP |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
decreases expression |
EXP |
10 |
87,771,337 |
87,800,960 |
RGD:6480464 |
CTD |
| G |
Tpbg |
trophoblast glycoprotein |
|
decreases expression |
EXP |
8 |
91,075,960 |
91,079,329 |
RGD:6480464 |
CTD |
| G |
Tpd52l1 |
tumor protein D52-like 1 |
|
increases expression |
EXP |
1 |
26,788,964 |
26,951,930 |
RGD:6480464 |
CTD |
| G |
Trhr |
thyrotropin releasing hormone receptor |
|
increases expression |
EXP |
7 |
80,050,671 |
80,095,991 |
RGD:6480464 |
CTD |
| G |
Trim54 |
tripartite motif-containing 54 |
|
increases expression |
EXP |
6 |
25,218,008 |
25,237,575 |
RGD:6480464 |
CTD |
| G |
Tspo |
translocator protein |
|
increases expression |
EXP |
7 |
121,597,084 |
121,599,342 |
RGD:6480464 |
CTD |
| G |
Tubb5 |
tubulin, beta 5 class I |
|
decreases expression |
EXP |
20 |
3,060,224 |
3,090,776 |
RGD:6480464 |
CTD |
| G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
|
decreases expression |
EXP |
3 |
155,800,357 |
155,802,757 |
RGD:6480464 |
CTD |
| G |
Vcan |
versican |
|
decreases expression |
EXP |
2 |
19,712,629 |
19,801,443 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
affects expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Wars |
tryptophanyl-tRNA synthetase |
|
decreases expression |
EXP |
6 |
133,200,866 |
133,232,048 |
RGD:6480464 |
CTD |
| G |
Xpo1 |
exportin 1, CRM1 homolog (yeast) |
|
decreases expression |
EXP |
14 |
103,943,249 |
103,978,717 |
RGD:6480464 |
CTD |
| G |
Zfp36 |
zinc finger protein 36 |
|
increases expression |
EXP |
1 |
83,486,643 |
83,489,123 |
RGD:6480464 |
CTD |
cortisone
|
| G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
|
multiple interactions |
ISO |
11 |
79,908,291 |
79,911,065 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
|
multiple interactions |
ISO |
13 |
109,063,491 |
109,089,468 |
RGD:6480464 |
CTD |
| G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
|
affects metabolic processing |
ISO |
13 |
109,063,491 |
109,089,468 |
RGD:6480464 |
CTD |
| G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
|
increases metabolic processing |
ISO |
13 |
109,063,491 |
109,089,468 |
RGD:6480464 |
CTD |
| G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
|
increases chemical synthesis |
ISO |
19 |
35,336,342 |
35,341,585 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects binding |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases activity |
ISO |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
increases expression |
EXP |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
| G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
|
multiple interactions |
EXP |
1 |
23,501,257 |
23,506,651 |
RGD:6480464 |
CTD |
testosterone
|
| G |
Tmem52 |
transmembrane protein 52 |
|
decreases expression |
ISO |
5 |
172,293,187 |
172,294,894 |
RGD:6480464 |
CTD |
| G |
Trex1 |
three prime repair exonuclease 1 |
|
multiple interactions |
ISO |
8 |
114,071,508 |
114,072,509 |
RGD:6480464 |
CTD |
Term paths to the root
| Path 1 |
CHEBI ontology |
501881 |
 |
chemical entity |
501881 |
 |
group |
456662 |
 |
inorganic group |
275854 |
 |
oxo group |
169689 |
 |
organic oxo compound |
169689 |
 |
carbonyl compound |
169689 |
 |
ketone |
31633 |
 |
oxo steroid |
13546 |
 |
3-oxo steroid |
12046 |
 |
(25S)-dafachronic acid |
0 |
 |
(5alpha,22S,24R)-22-hydroxyergostan-3-one |
0 |
 |
11beta-hydroxyandrost-4-ene-3,17-dione |
0 |
 |
16alpha-hydroxyandrost-4-ene-3,17-dione |
0 |
 |
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one |
533 |
 |
17beta-hydroxy-5alpha-androstan-3-one |
573 |
 |
19-hydroxyandrost-4-ene-3,17-dione |
0 |
 |
20-hydroxy-3-oxopregn-4-en-21-al |
0 |
 |
3,17-dioxoandrost-4-en-19-al |
0 |
 |
3-dehydro-4-carboxyzymosterol |
0 |
 |
3-dehydro-4-methylzymosterol |
0 |
 |
3-dehydro-6-deoxoteasterone |
0 |
 |
3-dehydroecdysone |
0 |
 |
3-dehydroteasterone |
0 |
 |
3-oxo Delta(4)-steroid + |
2529 |
 |
3-oxo Delta(5)-steroid + |
0 |
 |
3-oxo Delta(7)-steroid + |
0 |
 |
4,5-dihydrocortisone + |
0 |
 |
5alpha-androst-16-en-3-one |
0 |
 |
5alpha-campestan-3-one |
0 |
 |
5alpha-cholestan-3-one |
0 |
 |
5alpha-pregnane-3,20-dione |
14 |
 |
5beta-cholestan-3-one |
0 |
 |
5beta-pregnane-3,20-dione |
0 |
 |
6-methylprednisolone + |
52 |
 |
6beta-hydroxytestosterone |
4 |
 |
7alpha,12alpha,24-trihydroxy-5beta-cholestan-3-one + |
0 |
 |
7alpha,12alpha,24-trihydroxycholest-4-en-3-one + |
0 |
 |
7alpha,12alpha,26-trihydroxy-5beta-cholestan-3-one |
0 |
 |
7alpha,12alpha,26-trihydroxycholest-4-en-3-one |
0 |
 |
7alpha,12alpha-dihydroxy-5beta-cholestan-3-one |
0 |
 |
7alpha,12alpha-dihydroxycholest-4-en-3-one |
0 |
 |
7alpha,24-dihydroxy-5beta-cholestan-3-one + |
0 |
 |
7alpha,24-dihydroxycholest-4-en-3-one + |
0 |
 |
7alpha,26-dihydroxy-5beta-cholestan-3-one |
0 |
 |
7alpha,26-dihydroxycholest-4-en-3-one |
0 |
 |
7alpha-hydroxy-5beta-cholestan-3-one |
0 |
 |
7alpha-hydroxyandrost-4-ene-3,17-dione |
0 |
 |
7alpha-hydroxycholest-4-en-3-one |
2 |
 |
9,11alpha-epoxypregn-4-ene-3,20-dione |
0 |
 |
9alpha-hydroxyandrosta-1,4-diene-3,17-dione |
0 |
 |
Delta(1)-dihydrotestosterone |
0 |
 |
LD-norgestrel |
0 |
 |
alclometasone |
0 |
 |
alclometasone dipropionate |
10 |
 |
aldosterone + |
122 |
 |
aldosterone hemiacetal |
0 |
 |
algestone + |
0 |
 |
amcinonide |
0 |
 |
androst-4-ene-3,17-dione |
59 |
 |
androsta-1,4-diene-3,17-dione |
0 |
 |
androstane-3,17-dione + |
0 |
 |
betamethasone + |
18 |
 |
betamethasone valerate |
9 |
 |
boldenone |
1 |
 |
budesonide |
76 |
 |
campest-4-en-3-one |
0 |
 |
cholest-4-en-3-one |
0 |
 |
corticosterone + |
337 |
 |
cortisol + |
193 |
 |
cortisone + |
12 |
 |
cyproterone + |
63 |
 |
cyproterone acetate |
60 |
 |
deoxycortisol + |
13 |
 |
dexamethasone + |
2938 |
 |
drospirenone |
8 |
 |
dydrogesterone |
18 |
 |
eplerenone |
0 |
 |
etonogestrel |
6 |
 |
finasteride |
19 |
 |
fludrocortisone |
8 |
 |
flumethasone + |
0 |
 |
flumethasone pivalate |
0 |
 |
halosterol A |
0 |
 |
hydrocortamate + |
0 |
![click to br]() | |
|